Issue link: https://viewer.e-digitaledition.com/i/322317
COV ER FE AT UR E COV ER FE AT UR E "Transcatheter aortic valve replacement has proven to be paradigm-shifting in the management of high-risk and inoperable patients with aortic stenosis, for whom there was previously no other option. It's a viable option for patients who would otherwise, by definition, be terminally ill." — Jock Nash McCullough, MD, Vice Chair of the Heart & Vascular Hospital at Hackensack University Medical Center P H YS I C I A N S P OT LI G H T JOCK NASH MCCULLOUGH, MD, Vice Chair of the Heart & Vascular Hospital at Hackensack University Medical Center (HackensackUMC), received his medical degree from Rutgers New Jersey Medical School, where he also served his residency in general surgery and was administrative chief resident in surgery. Throughout his 20 years of practice, following additional postdoctoral training in transplantation and mechanical assist at the University of Pittsburgh Medical Center, Dr. McCullough has been at the forefront of cardiothoracic innovation and was part of the teams that performed the first transcatheter aortic valve replacement (TAVR) and transapical TAVR procedures at HackensackUMC. Thomas Cocke, MD, attending inter- ventional cardiologist at HackensackUMC, received his medical degree from State University of New York at Stony Brook and served a residency at Jacobi Medical Center. Following fellowships at Mt. Sinai Medical Center and Columbia Presbyterian Medical Center, Dr. Cocke has focused his practice on structural heart disease, performing more than 500 procedures in 20-plus years of practice. For more information about the TAVR procedure at Hacken sackUMC, visit hackensackumc.org. ■ COV ER FE AT UR E The mounted Sapien transcatheter aortic valve prosthesis removes the initial sheath and places the delivery sheath through the apex of the heart, and another surgeon inserts the catheter carrying the new valve. The cardiac surgeon then positions and deploys the valve following a process similar to transfemorally approached TAVR. "The division of labor we employ during the different approaches to TAVR is the most efficient manner with which to perform each procedure," Dr. Cocke explains. "The transfemoral approach requires a higher degree of catheter manipulation to deploy the valve in place, while the transapical approach relies more heavily on surgical prowess to expose the apex of the heart." Early Evaluation for Lifesaving Treatment TAVR can mean a return to function and possibly longer life for patients who traditionally had no hope for treatment of their aortic stenosis. Because the disease progressively worsens, early referral can make a dramatic difference in the quality of a patient's golden years. "Any time patients have hemodynamically meaningful aortic stenosis and symptoms, including shortness of breath, chest pain with any type of exertion, or syncope, they should be referred so we can evaluate them for aortic valve therapy," Dr. McCullough notes. "We offer all forms of aortic valve replace- ment to treat the spectrum of patients with aortic stenosis, and the addition of TAVR broadens our treatment parameters even further." Members of the TAVR team at the Heart & Vascular Hospital at HackensackUMC. Row 1: (L-R) Therese Palazzo, Director; Josefina Martinez, RN; Andrea Ramos, CVT tech; Edwin Nunez, perfusion tech; Anita Stechow, perfusionist; Larry Abrams, MD, anesthesiologist. Row 2: Maria Jain-Cananero, RN; Brenda DiMeglio, TAVR representative; Elly Delaportas, APN; David Lai, RN; Al Londono, RN; Rose Cambridge, RN; Jeff Hulko, CVT tech; Elly Elmann, MD, surgeon; Jose Alvarado, CVT tech; Thomas Cocke, MD, cardiologist; John Rokosny, CVT tech; Pranaychandra Vaidya, MD, cardiologist; Jock McCullough, MD, surgeon; Bill Monahan, TAVR representative; Emma Babenko, surgical tech; Debby Madden, perfusionist 8 | Lower Hudson/Bronx MD NEWS ■ M D N E W S . CO M

